These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082 [TBL] [Abstract][Full Text] [Related]
24. Saquinavir plus ritonavir open-label study recruiting. AIDS Patient Care STDS; 1996 Oct; 10(5):308. PubMed ID: 11361524 [No Abstract] [Full Text] [Related]
25. Combo approved for HIV treatment. Nurse Pract; 2004 Mar; 29(3):40. PubMed ID: 15052701 [No Abstract] [Full Text] [Related]
26. Protease inhibitors at a glance... Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198 [TBL] [Abstract][Full Text] [Related]
27. Soft gel saquinavir has high exposure. AIDS Alert; 1997 Dec; 12(12):143-4. PubMed ID: 11364835 [TBL] [Abstract][Full Text] [Related]
28. FDA clearance for ritonavir in children with AIDS. AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361797 [No Abstract] [Full Text] [Related]
35. Saquinavir/low-dose ritonavir: its use in HIV infection. Johnson M; Peters B AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107 [TBL] [Abstract][Full Text] [Related]
37. Nelfinavir is number 4 -- but should it bat cleanup, or lead off? Mascolini M J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427 [TBL] [Abstract][Full Text] [Related]
38. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Moyle GJ; Sadler M; Buss N Clin Infect Dis; 1999 Feb; 28(2):403-4. PubMed ID: 10064262 [No Abstract] [Full Text] [Related]